Track topics on Twitter Track topics that are important to you
Focus on Wearable Electronics, In-mold Electronics, Consumer Electronics and Healthcare
BRISTOL, U.K. (PRWEB) February 23, 2017
DuPont Electronics & Communications (DuPont) and Holst Centre today announced the third extension of their successful long-term collaboration, which is focused on advanced materials for the printed electronics industry. As a full partner in the Printed Electronics program, DuPont will contribute new materials and research samples targeted toward Holst’s active projects in the areas of wearable electronics, in-mold electronics, consumer electronics and healthcare.
“We’re pleased to extend our collaboration with Holst Centre, continuing to work together in advancing new developments in printed electronics,” said Kerry Adams, printed electronics market segment manager, DuPont. “In addition to advancing the technology, the collaboration provides us with valuable insights into the needs and requirements of other Holst partners, including end-users and equipment suppliers, enabling open innovation and accelerating product and application development.”
In this next phase, the emphasis of the collaboration will be on developing and testing complete complementary material systems and successfully creating working demonstrators and prototypes, with the development of commercial products as the end goal. In particular, the collaboration will focus on screen printed and ink-jet electronic inks and pastes, flat bed and roll-to-roll processing, and conventional oven as well as photonic curing/sintering systems.
Over the life of the DuPont/Holst Centre collaboration, results have included the development of new nano-Ag inks and pastes, leading to the commercialization of DuPont’s best in class conductive ink-jet silver ink, PE410, announced and featured at LOPEC in Munich, Germany, in April 2016. Most recently, Holst presented their wearable smart shirt design in the DuPont booth at the Wearables Expo in Tokyo, Japan, from Jan. 18-20, 2017. Other achievements have included the successful implementation of DuPont inks and pastes enabling production of smart garments, flexible sensors and smart blister medical packaging, as well as in-mold electronics, and Organic Photovoltaic (OPV) and Organic Light Emitting Diode (OLED) lighting demos and prototypes.
“The collaboration between DuPont and Holst Centre continues to drive exciting advancements in printed electronics,” said Jeroen van den Brand, program director ‘printed electronics’, Holst Centre. “We are excited to continue to explore new technologies and opportunities alongside a recognized industry leader.”
DuPont will showcase the latest developments in wearable electronics, in-mold electronics, consumer electronics and healthcare at stand B0 308 at LOPEC, the International Exhibition and Conference for Printed Electronics, March 28 – 30, 2017, in Munich, Germany.
Holst Centre is an independent open-innovation R&D centre that develops generic technologies for wireless sensor technologies and flexible electronics, that contribute to answering global societal challenges in healthcare, lifestyle, sustainability and the Internet of Things. A key feature of Holst Centre is its partnership model with industry and academia around shared roadmaps and programs. It is this kind of cross-fertilization that enables Holst Centre to tune its scientific strategy to industrial needs. Holst Centre was set up in 2005 by imec (Flanders, Belgium) and TNO (The Netherlands) with support from the Dutch Ministry of Economic Affairs and the Government of Flanders. Holst Centre has over 200 employees from around 28 nationalities and a commitment from more than 50 industrial partners. For more information about Holst Centre, please visit http://www.holstcentre.com.
DuPont Electronics & Communications is a leading innovator and high-volume supplier of electronic inks and pastes that offers a broad range of printed electronic materials commercially available today. The growing portfolio of DuPont electronic inks is used in many applications, including forming conductive traces, capacitor and resistor elements, and dielectric and encapsulating layers that are compatible with many substrate surfaces including polymer, glass and ceramic. For more information, visit http://www.advancedmaterials.dupont.com.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
# # #
Forward-Looking Statements: This document contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company’s strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December 11, 2015, with The Dow Chemical Company pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
For the original version on PRWeb visit: http://www.prweb.com/releases/dupont-flexible-inks/holst-centre-electronics/prweb14092124.htmNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...